ArticleBreast cancer research : BCR2025
Breast cancer risk during oral contraceptive use in women with high polygenic risk.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral contraceptive (OC) use is widespread globally. Despite their significant benefits, concerns persist about a potential rise in breast cancer risk linked to their use. Genetic predisposition also influences breast cancer risk; however, its interaction with OC use remains inconclusive. This study aims to explore the association between OC use and breast cancer risk in women with varying genetic predispositions to breast cancer, as measured by polygenic risk scores (PRS).
methodA total of 257,185 white female participants from the UK Biobank were included. Time-varying Cox regression was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) to examine the association between OC and invasive breast cancer events, stratified by PRS. Age was used as the primary time scale, and analyses were adjusted for year of birth, Townsend Deprivation Index, body mass index, smoking status, age at menarche, menopausal status, family history of breast cancer, parity, hormone replacement therapy use, history of hysterectomy, as well as genetic principal components.
resultsCurrent use of OC was associated with an increased risk of breast cancer, with a HR of 1.21 (95% CI: 1.03–1.41). In contrast, previous use showed no association (HR = 0.99, 95% CI: 0.92–1.05). Genetic risk, as measured by the PRS, was strongly associated with breast cancer risk (P < 0.001). Individuals in the highest PRS decile had approximately three times higher risk compared to those in the mid deciles. Importantly, for the association between current OC use and breast cancer risk, a statistically significant trend was observed across both PRS deciles (P = 0.04) and tertiles (P = 0.05), with decreasing HRs as genetic risk increased. Specifically, the HR for current OC use was 1.43 (95% CI: 1.02–2.01) in the lowest PRS tertile, 1.14 (95% CI: 0.89–1.45) in the middle tertile, and 0.96 (95% CI: 0.80–1.14) in the highest tertile.
conclusionBoth OC use and a high PRS increase the risk of breast cancer. There is a trend toward a decreased relative risk associated with OC use among those with higher genetic predisposition. Therefore, there is no evidence to suggest that women with a high genetic risk for breast cancer are more adversely affected by OC use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.